Insulin antagonism of normal and diabetic albumin after liver perfusion

Expert consensus on the diagnosis and treatment of end-stage liver disease complicated by infections.

Hepatology international·2024

Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation.

Alimentary pharmacology & therapeutics·2017

Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient Outcomes.

The American journal of gastroenterology·2017

Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis.

Alimentary pharmacology & therapeutics·2016

Hepatic degradation of insulin and the release of its component A and B chains.

Irish journal of medical science·2016

HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients.

Alimentary pharmacology & therapeutics·2016

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Lancet (London, England)·2026

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

Lancet (London, England)·2026

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Lancet (London, England)·2026

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.

Lancet (London, England)·2026

Visualizing Cell Type-Specific Glycan Profiles in Tissue Sections With Glycan Painting.

Bio-protocol·2026

Genomic profiling of estrogen-related receptor identifies adult adipocyte-specific targets in Drosophila.

G3 (Bethesda, Md.)·2026

Sphingolipid Dysregulation in Type 2 Diabetes and Its Microvascular Complications.

International journal of molecular sciences·2026

β-cell adaptation to increased insulin demand is a swift and dynamic process orchestrated by unfolded protein response.

Cell communication and signaling : CCS·2026

Dual purine starvation triggers an Iml1-Whi2-dependent autophagy pathway for survival in yeast.

Autophagy·2026

Ubiquitylation of unbranched glycogen and glycogenin-1 in branching enzyme-deficient cells.

Biochemical and biophysical research communications·2026

Related Experiment Videos

Insulin antagonism of normal and diabetic albumin after liver perfusion

Related Concept Videos

Expert consensus on the diagnosis and treatment of end-stage liver disease complicated by infections.

Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation.

Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient Outcomes.

Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis.

Hepatic degradation of insulin and the release of its component A and B chains.

HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients.

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.

Visualizing Cell Type-Specific Glycan Profiles in Tissue Sections With Glycan Painting.

Genomic profiling of estrogen-related receptor identifies adult adipocyte-specific targets in Drosophila.

Sphingolipid Dysregulation in Type 2 Diabetes and Its Microvascular Complications.

β-cell adaptation to increased insulin demand is a swift and dynamic process orchestrated by unfolded protein response.

Dual purine starvation triggers an Iml1-Whi2-dependent autophagy pathway for survival in yeast.

Ubiquitylation of unbranched glycogen and glycogenin-1 in branching enzyme-deficient cells.

Related Experiment Videos

Insulin antagonism of normal and diabetic albumin after liver perfusion

Related Concept Videos

Related Articles